
In a phase 3 trial, the investigational oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by nearly 60% in adults with or at risk for ASCVD.

Hayden is an associate editor for The American Journal of Managed Care® (AJMC®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.

In a phase 3 trial, the investigational oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by nearly 60% in adults with or at risk for ASCVD.

Experts at AHA 2025 outlined how digital tools, inclusive trials, and safer deprescribing can reshape cardiovascular care for aging adults.

Research shows how low-dose aspirin, lifestyle habits, and the Life’s Essential 8 checklist can affect cardiovascular risk in patients with type 2 diabetes.

Lisa Taylor-Swanson, PhD, explains how including Indigenous and Hispanic women in conversations around menopause care helps fine-tune interventions.

Despite social media frenzy, there is limited evidence around testosterone’s impact on muscle, mood, and other menopausal symptoms.

Oncology experts discuss the rapid advancements in cancer diagnostics and treatments, emphasizing the need for equitable access and infrastructure improvements.

Payers cited high upfront costs, long-term uncertainty, and narrow coverage criteria as factors continuing to limit access and reimbursement innovation.

Attorney General Ken Paxton claims the manufacturers marketed acetaminophen toward pregnant women despite the “known dangers” to unborn children.

New data reinforce elinzanetant’s safety, efficacy, and ability to improve sleep disturbances in menopausal women, independent of vasomotor symptom relief.

Early and lifelong trauma can intensify menopause symptoms and accelerate cardiovascular and brain aging, according to research.

Preclinical data suggest a possible synergistic interaction between estrogen and GLP-1 signaling, explains Regina Castaneda, MD.

US safety data show that elinzanetant caused few adverse events and no new liver-related concerns in women, James Simon, MD, explains.

Hormonal shifts drive fat redistribution, muscle loss, and bone decline—all risk factors for cardiovascular disease in women, says Brooke Aggarwal, EdD.

Treating vasomotor symptoms, sleep disturbance, and mood disorders can remove barriers to weight loss for women during menopause, experts say.

Which hormonal contraceptives are still safe, when should women stop using them, and what other benefits do they offer during the menopause transition?

Different cultural, linguistic, and systemic barriers could impact how Indigenous and Hispanic women access menopause care, said Lisa Taylor-Swanson, PhD.

Can women feel relief from tinnitus and burning mouth syndrome during perimenopause and menopause?

Experts also explained how hormone therapy can benefit women managing chronic conditions such as diabetes and hypertension on top of their menopause.

Researchers will present new findings on how menopause affects cardiovascular, brain, metabolic, and digestive health.

The 7-mg and 14-mg oral semaglutide tablets are now indicated to reduce the risk of major adverse cardiovascular events in adults with diabetes.

Remote monitoring and algorithm-based tools help pharmacists balance complex workloads in value-based care, says Lindsey Valenzuela, PharmD.

Adults with diabetes were 24% less likely to visit an emergency department in 2021 than in 2019.

Lindsey Valenzuela, PharmD, explains how value-based models empower a single pharmacist to manage multiple layers of these disease states.

The number of Black, Hispanic, and Latino students admitted into medical schools fell as rates increased for White and Asian students.

The new indication allows doctors to use upadacitinib before tumor necrosis factor–blocking agents when those treatments are clinically inadvisable.

Lindsey Valenzuela, PharmD, explains how pharmacists can prevent drug interactions and improve coordination for women with arrhythmia and chronic disease.

Lindsey Valenzuela, PharmD, explains how cost, coverage gaps, and tech literacy hinder women’s access to early arrhythmia detection tools.

Lindsey Valenzuela, PharmD, explains how atypical symptoms, research gaps, and care inequities delay arrhythmia detection in women.

Laxmi Patel of Savista discusses how the Budget Reconciliation Act could widen Medicaid coverage gaps and strain hospitals across states.

A CCS report found that pharmacists lack time for diabetes education as workloads rise, worsening disparities and threatening adherence.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
